These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8899856)

  • 1. Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model.
    Evans LA; Genereux PE; Gibbs EM; Sutton SC
    Pharm Res; 1996 Oct; 13(10):1585-7. PubMed ID: 8899856
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting injection site muscle damage. II: Evaluation of extended release parenteral formulations in animal models.
    Sutton SC; Evans LA; Rinaldi MT; Norton KA
    Pharm Res; 1996 Oct; 13(10):1514-8. PubMed ID: 8899843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting injection site muscle damage. I: Evaluation of immediate release parenteral formulations in animal models.
    Sutton SC; Evans LA; Rinaldi MT; Norton KA
    Pharm Res; 1996 Oct; 13(10):1507-13. PubMed ID: 8899842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release.
    Lefebvre HP; Laroute V; Braun JP; Lassourd V; Toutain PL
    Vet Res; 1996; 27(4-5):343-61. PubMed ID: 8822606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The loss of creatine phosphokinase (CK) from intramuscular injection sites in rabbits. A predictive tool for local toxicity [proceedings].
    Svendsen O; Rasmussen F; Nielsen P; Steiness E
    Arch Toxicol Suppl; 1979; (2):409. PubMed ID: 288353
    [No Abstract]   [Full Text] [Related]  

  • 6. Rat paw-lick/muscle irritation model for evaluating parenteral formulations for pain-on-injection and muscle damage.
    Chellman GJ; Faurot GF; Lollini LO; McCullough TE
    Fundam Appl Toxicol; 1990 Nov; 15(4):697-709. PubMed ID: 2086314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tests for local toxicity of intramuscular drug preparations: comparison of in vivo and in vitro methods.
    Svendsen O; Højelse F; Bagdon RE
    Acta Pharmacol Toxicol (Copenh); 1985 Feb; 56(2):183-90. PubMed ID: 3993387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue tolerance of azithromycin after intramuscular administration to rabbits.
    Escudero E; Fernández-Varón E; Marín P; Espuny A; Nájera MD; Cárceles CM
    Res Vet Sci; 2006 Dec; 81(3):366-72. PubMed ID: 16530237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained release of liposome-encapsulated enrofloxacin after intramuscular administration in rabbits.
    Cabanes A; Reig F; Antón JM; Arboix M
    Am J Vet Res; 1995 Nov; 56(11):1498-501. PubMed ID: 8585663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The L6 muscle cell line as a tool to evaluate parenteral products for irritation.
    Laska DA; Williams PD; Reboulet JT; Morris RM
    J Parenter Sci Technol; 1991; 45(2):77-82. PubMed ID: 2051260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local tissue damage after intramuscular injections in rabbits and pigs: quantitation by determination of creatine kinase activity at injection sites.
    Diness V
    Acta Pharmacol Toxicol (Copenh); 1985 May; 56(5):410-5. PubMed ID: 4036633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of enrofloxacin after intravenous and intramuscular injection in rabbits.
    Cabanes A; Arboix M; Garcia Anton JM; Reig F
    Am J Vet Res; 1992 Nov; 53(11):2090-3. PubMed ID: 1334640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability of muscle creatine kinase in sheep. Application to the assessment of local tolerance to injectable veterinary formulations].
    Verlinde V; Mikaelian I; Laurentie M; Sanders P; Poul JM
    Vet Res; 1996; 27(2):133-46. PubMed ID: 8721293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro model to evaluate muscle damage following intramuscular injections.
    Brazeau GA; Fung HL
    Pharm Res; 1989 Feb; 6(2):167-70. PubMed ID: 2762216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pain and irritation following local administration of parenteral formulations using the rat paw lick model.
    Gupta PK; Patel JP; Hahn KR
    J Pharm Sci Technol; 1994; 48(3):159-66. PubMed ID: 8069518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo non-invasive quantification of muscle damage following a single intramuscular injection of phenylbutazone in sheep.
    Houpert P; Serthelon JP; Lefebvre HP; Toutain PL; Braun JP
    Vet Hum Toxicol; 1995 Apr; 37(2):105-10. PubMed ID: 7631487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Creatine phosphokinase, myocardial infarction and intramuscular injection].
    Sauerwein HP; Brouwer T; Dunning AJ
    Ned Tijdschr Geneeskd; 1975 Sep; 119(37):1399-402. PubMed ID: 1178074
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of an in vitro model for the assessment of muscle damage from intramuscular injections: in vitro-in vivo correlation and predictability with mixed solvent systems.
    Brazeau GA; Fung HL
    Pharm Res; 1989 Sep; 6(9):766-71. PubMed ID: 2813273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Demonstration of tissue lesions after intramuscular injection by determination of creatine kinase in blood].
    Chavez Moreno J; Bickhardt K
    Dtsch Tierarztl Wochenschr; 1997 Dec; 104(12):512-5. PubMed ID: 9451857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The loss of creatine phosphokinase (CK) from intramuscular injection sites in rabbits. A predictive tool for local toxicity.
    Svendsen O; Rasmussen F; Nielsen P; Steiness E
    Acta Pharmacol Toxicol (Copenh); 1979 May; 44(5):324-8. PubMed ID: 474142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.